{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+CDI&page=2", "query": { "condition": "Recurrent CDI", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+CDI&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-27T10:00:19.479Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02299570", "title": "Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Enterocolitis Clostridium Difficile Recurrent" ], "interventions": [ { "name": "RBX2660 (microbiota suspension)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Rebiotix Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2014-12", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2021-01-15", "last_synced_at": "2026-06-27T10:00:19.479Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02299570" }, { "nct_id": "NCT05835219", "title": "REBYOTA™ Prospective Registry", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrence of Clostridium Difficile Infection" ], "interventions": [ { "name": "REBYOTA™", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2023-06-19", "completion_date": "2025-08-29", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-06-27T10:00:19.479Z", "location_count": 42, "location_summary": "Chandler, Arizona • Chula Vista, California • Murrieta, California + 36 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Murrieta", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05835219" }, { "nct_id": "NCT03788434", "title": "Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Difficile Infection Recurrence", "Clostridium Difficile Infection", "Clostridium Difficile", "Clostridioides Difficile Infection Recurrence", "Clostridioides Difficile Infection", "Clostridioides Difficile", "CDI" ], "interventions": [ { "name": "VE303", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vedanta Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2019-02-08", "completion_date": "2021-09-15", "has_results": true, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-06-27T10:00:19.479Z", "location_count": 29, "location_summary": "Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Canoga Park", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03788434" }, { "nct_id": "NCT01259726", "title": "Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Difficile Infection" ], "interventions": [ { "name": "VP20621", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2011-06-27", "completion_date": "2013-06-11", "has_results": true, "last_update_posted_date": "2021-06-10", "last_synced_at": "2026-06-27T10:00:19.479Z", "location_count": 42, "location_summary": "Modesto, California • Palm Desert, California • Sacramento, California + 39 more", "locations": [ { "city": "Modesto", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01259726" }, { "nct_id": "NCT03829475", "title": "ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Inflammatory Bowel Diseases", "Clostridium Difficile Infection" ], "interventions": [ { "name": "Bezlotoxumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fecal Microbiota Transplantation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2020-01-01", "completion_date": "2025-06-01", "has_results": true, "last_update_posted_date": "2025-12-09", "last_synced_at": "2026-06-27T10:00:19.479Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03829475" }, { "nct_id": "NCT03497806", "title": "Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Difficile Infection", "Recurrent Clostridium Difficile Infection", "C. Diff", "CDI", "Recurrent C. Diff", "rCDI", "C. Difficile", "Recurrent CDI", "FMT", "Fecal Microbiota", "Fecal Transplant" ], "interventions": [ { "name": "CP101", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Finch Research and Development LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2018-05-01", "completion_date": "2021-04-01", "has_results": true, "last_update_posted_date": "2022-08-30", "last_synced_at": "2026-06-27T10:00:19.479Z", "location_count": 53, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03497806" }, { "nct_id": "NCT04626947", "title": "Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Inflammatory Bowel Diseases", "Ulcerative Colitis", "Crohn Disease", "C. Diff. Infections" ], "interventions": [ { "name": "Bezlotoxumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "David Binion, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-10-14", "completion_date": "2024-05-31", "has_results": true, "last_update_posted_date": "2025-06-05", "last_synced_at": "2026-06-27T10:00:19.479Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04626947" }, { "nct_id": "NCT05831189", "title": "A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clostridium Difficile Infection Recurrence" ], "interventions": [ { "name": "RBX2660", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2023-04-21", "completion_date": "2025-01-17", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-06-27T10:00:19.479Z", "location_count": 12, "location_summary": "North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Camarillo", "state": "California" }, { "city": "Hamden", "state": "Connecticut" }, { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Gurnee", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05831189" }, { "nct_id": "NCT03880539", "title": "Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Clostridium Difficile Infection Recurrence" ], "interventions": [ { "name": "bezlotoxumab", "type": "DRUG" }, { "name": "Vancomycin Oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2019-06-25", "completion_date": "2021-11-18", "has_results": false, "last_update_posted_date": "2022-05-26", "last_synced_at": "2026-06-27T10:00:19.479Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03880539" }, { "nct_id": "NCT04000555", "title": "Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Clostridium Difficile Infection", "Clostridium Difficile Infection Recurrence" ], "interventions": [ { "name": "Oral Vancomycin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2019-09-01", "completion_date": "2022-06-11", "has_results": false, "last_update_posted_date": "2023-04-21", "last_synced_at": "2026-06-27T10:00:19.479Z", "location_count": 2, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04000555" } ] }